Authors
Loading...
Retrospective analysis highlights a 3-day busulfan regimen improving overall survival in younger AML patients, indicating it as the optimal choice.
Park et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: